Indications and Clinical Use:
XPOVIO® (selinexor) is indicated in combination with bortezomib and dexamethasone for
the treatment of adult patients with multiple myeloma who have received at least one prior
therapy.
No overall differences in effectiveness were observed between patients ≥ 65
years of age and younger patients. Older patients had a higher incidence of serious adverse
reactions and discontinuation due to an adverse reaction than younger patients.
Relevant Warnings and Precautions:
- Maintenance of adequate fluid and caloric intake.
- Driving and operating machinery.
- Severe or life-threatening hyponatremia.
- Nausea, vomiting, and diarrhea.
- Weight loss and anorexia.
- Life-threatening thrombocytopenia.
- Life-threatening neutropenia.
- Tumour lysis syndrome.
- Serious and fatal infections.
- Monitoring platelet, hemoglobin, and white blood cell counts, sodium level, patient weight,
nutritional status, and volume status.
- Life-threatening neurologic toxicities.
- New onset or exacerbation of cataract.
- Fertility impairment in females and males of reproductive potential.
- Use of contraception in females of reproductive potential and in males with a female partner of
reproductive of potential.
- Use in pregnant or breastfeeding women.
- Use in pediatric and geriatric patients.
For More Information:
Please consult the Product Monograph at www.xpoviopm.ca for full prescribing details, including
important information relating to adverse reactions, drug interactions, and dosing information which
have not been discussed in this piece.
The Product Monograph is also available by calling
us at 1-866-542-7500.